Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications

Marc A. Rodger, Marc Carrier, Gr'egoire Le Gal, Ida Martinelli, Annalisa Perna, Evelyne Rey, J. I P De Vries, Jean Christophe Gris

Research output: Contribution to journalArticle

Abstract

A 35-year-oldwomanwith recurrent severe placenta-mediated pregnancy complications in her 2 pregnancies asks: Will lowmolecular- weight heparin help prevent recurrent placenta-mediated pregnancy complications in my next pregnancy? We performed a meta-analysis of randomized controlled trials (RCTs) comparing low-molecular-weight heparin (LMWH) vs no LMWH for the prevention of recurrent placenta-mediated pregnancy complications. We identified six RCTs that included a total of 848 pregnant women with prior placenta-mediated pregnancy complications. The primary outcome was a composite of pre-eclampsia (PE), birth of a small-for-gestational-age (SGA) newborn (20 weeks. Overall, 67 (18.7%) of 358 of women being given prophylactic LMWH had recurrent severe placenta-mediated pregnancy complications compared with 127 (42.9%) of 296 women with no LMWH (relative risk reduction, 0.52; 95% CI, 0.32 to 0.86; P 5 .01; I2, 69%, indicating moderate heterogeneity). We identified similar relative risk reductions with LMWH for individual outcomes, including any PE, severe PE, SGA

Original languageEnglish
Pages (from-to)822-828
Number of pages7
JournalBlood
Volume123
Issue number6
DOIs
Publication statusPublished - Feb 6 2014

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Fingerprint Dive into the research topics of 'Meta-analysis of low-molecular-weight heparin to prevent recurrent placenta-mediated pregnancy complications'. Together they form a unique fingerprint.

  • Cite this